Form 4: Director Chacon Quiros Boosts ESTA Holdings Stake

Establishment Labs Holdings Director Juan Jose Chacon Quiros acquired 10,285 common shares and 14,906 stock options, increasing his beneficial ownership.

Summary

• Director Juan Jose Chacon Quiros acquired 10,285 common shares of Establishment Labs Holdings Inc. (ESTA) at a price of $0.
• He also acquired 14,906 stock options with an exercise price of $36.46.
• These acquisitions represent an award of stock units and options under the Issuer's 2018 Equity Incentive Plan.
• The awards are subject to a vesting schedule, with one-fourth of the shares and options vesting on June 1, 2026, and annually thereafter, contingent on continued service.
• The grant was contingent upon the execution of a post-employment agreement, which was signed on August 3, 2025.
• Concurrently, Mr. Chacon Quiros entered into a consulting agreement effective June 1, 2025.
• Following these transactions, Mr. Chacon Quiros directly owns 224,433 common shares and 14,906 stock options.
• He indirectly owns 1,078,264 common shares through Sariel Group Ltd., disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director, even as an award, generally signals confidence and aligns management's interests with shareholders. The vesting schedule encourages long-term commitment. No negative information was disclosed.

Positives

• A director, Juan Jose Chacon Quiros, increased his direct beneficial ownership in Establishment Labs Holdings Inc. by acquiring 10,285 common shares and 14,906 stock options.
• The acquisition of shares and options, particularly as an equity incentive award, aligns management's long-term interests with those of shareholders.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned and structured approach to equity compensation.

Risks

• The vesting of the awarded stock units and options is contingent upon the reporting person continuing as a service provider through the specified vesting dates.

Future Outlook

The awarded stock units and options are subject to a multi-year vesting schedule, with one-fourth vesting annually starting June 1, 2026, contingent on the director's continued service to the company.

Management Comments

• The grant was contingent upon execution of a post-employment agreement, which was signed on August 3, 2025.
• Concurrently, the Reporting Person entered into a consulting agreement effective June 1, 2025.
• The Reporting Person disclaims beneficial ownership of the shares held by Sariel Group Ltd, except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the medical device or healthcare technology industry, where equity awards are commonly used to incentivize long-term performance and align management interests with shareholder value. The multi-year vesting schedule encourages continued service, a common strategy to retain key talent in competitive sectors.

Comparison to Industry Standards

• The use of equity incentive plans, such as the Issuer's 2018 Equity Incentive Plan, is a common practice across publicly traded companies, including peers in the medical aesthetics and breast implant market like Mentor Worldwide LLC (a Johnson & Johnson company) or Sientra, Inc.
• Granting restricted stock units or stock options with multi-year vesting schedules is a standard mechanism to retain key directors and executives, similar to compensation structures seen at companies like InMode Ltd. or Cutera, Inc., which also operate in related aesthetic markets.
• The exercise price of $36.46 for the options would typically be compared to the market price of ESTA shares on the grant date (August 3, 2025) to assess if they were granted at-the-money, in-the-money, or out-of-the-money, a common practice for evaluating the immediate value of such awards.

Corporate Governance

Related Party Transactions

• Juan Jose Chacon Quiros indirectly owns 1,078,264 common shares through Sariel Group Ltd., where he is a shareholder and has voting and dispositive power. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: Potential positive signal due to the director's increased equity stake, aligning his interests with long-term company performance. The equity awards represent a form of compensation that can lead to dilution, a standard consideration for shareholders.
• Employees: No direct impact on general employees is mentioned, but the structure of executive compensation can influence overall company culture and morale.

Next Steps

• Continued service of Juan Jose Chacon Quiros as a director and service provider.
• Vesting of one-fourth of the awarded stock units and options on June 1, 2026, and annually thereafter.

Key Dates

Recommendation

While the director's acquisition of shares and options, even as an award, can be seen as a positive signal of alignment with shareholder interests, a Form 4 filing primarily reports insider transactions and does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. It's an expected part of executive compensation. Investors should 'hold' and await more detailed financial reports or strategic updates for a more informed decision.

Keywords

Establishment Labs Holdings, ESTA, Form 4, Insider Transaction, Stock Award, Stock Option, Director Compensation, Equity Incentive Plan, Juan Jose Chacon Quiros